CN116323578A - 噻吩hsd17b13抑制剂及其用途 - Google Patents

噻吩hsd17b13抑制剂及其用途 Download PDF

Info

Publication number
CN116323578A
CN116323578A CN202180065663.XA CN202180065663A CN116323578A CN 116323578 A CN116323578 A CN 116323578A CN 202180065663 A CN202180065663 A CN 202180065663A CN 116323578 A CN116323578 A CN 116323578A
Authority
CN
China
Prior art keywords
alkyl
heterocycloalkyl
aryl
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180065663.XA
Other languages
English (en)
Chinese (zh)
Inventor
约书亚·奥丁戈
萨姆帕斯·库马尔·阿南丹
希瑟·凯·韦伯·许
文森特·弗洛里奥
沙布拉曼亚姆·贾纳德汉·坦特里
阿什赛亚玛尼·杰亚拉吉·杜拉斯瓦米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eni Pharmaceutical Co
Original Assignee
Eni Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eni Pharmaceutical Co filed Critical Eni Pharmaceutical Co
Publication of CN116323578A publication Critical patent/CN116323578A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202180065663.XA 2020-07-24 2021-07-23 噻吩hsd17b13抑制剂及其用途 Pending CN116323578A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063056165P 2020-07-24 2020-07-24
US63/056,165 2020-07-24
US202063113555P 2020-11-13 2020-11-13
US63/113,555 2020-11-13
PCT/US2021/042960 WO2022020714A1 (en) 2020-07-24 2021-07-23 Thiophene hsd17b13 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN116323578A true CN116323578A (zh) 2023-06-23

Family

ID=79729016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180065663.XA Pending CN116323578A (zh) 2020-07-24 2021-07-23 噻吩hsd17b13抑制剂及其用途

Country Status (6)

Country Link
US (1) US20230278978A1 (https=)
EP (1) EP4185381A4 (https=)
JP (1) JP2023537271A (https=)
CN (1) CN116323578A (https=)
TW (1) TW202220967A (https=)
WO (1) WO2022020714A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021377248B2 (en) * 2020-11-13 2025-12-18 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
WO2022216626A1 (en) * 2021-04-05 2022-10-13 Inipharm, Inc. Hydroxypyridine hsd17b13 inhibitors and uses thereof
CN118103038A (zh) 2021-08-20 2024-05-28 英安塔制药有限公司 17β-羟基类固醇脱氢酶13型抑制剂及其使用方法
KR20240122834A (ko) * 2021-12-15 2024-08-13 브리스톨-마이어스 스큅 컴퍼니 Rxfp1 효능제로서의 벤조티오펜 유도체
IL314415A (en) * 2022-01-26 2024-09-01 Inipharm Inc Thiazole 2-converted HSD17B13 inhibitors and uses thereof
PL4514782T3 (pl) 2022-05-19 2026-02-23 Astrazeneca Ab Związki amidoheteroaromatyczne przydatne w leczeniu chorób wątroby
JP2025523357A (ja) 2022-06-09 2025-07-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｓｄ１７ｂ１３阻害剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233246A (zh) * 1996-10-15 1999-10-27 默克专利股份公司 氨基噻吩羧基酰胺及其作为磷酸二酯酶抑制剂的用途
US20060217426A1 (en) * 2003-03-27 2006-09-28 Kirin Beer Kabushiki Kaisha Compound inhibiting in vivo phosphorous transport and medicine containing the same
CN101287728A (zh) * 2005-08-17 2008-10-15 先灵公司 新的高亲和力噻吩基和呋喃基激酶配体
US20150119426A1 (en) * 2012-05-04 2015-04-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Modulators of the relaxin receptor 1
CN105524053A (zh) * 2014-10-19 2016-04-27 广东东阳光药业有限公司 四氢苯并噻吩化合物
US20170096435A1 (en) * 2015-09-30 2017-04-06 Quartet Medicine, Inc. Sepiapterin reductase inhibitors
KR20170092126A (ko) * 2016-02-02 2017-08-10 부산대학교 산학협력단 Ppar, fxr 및 ampk 활성화 효능을 갖는 신규 티오펜 화합물 또는 이의 약제학적으로 허용 가능한 염 및 이의 의학적 용도
CN109563070A (zh) * 2016-08-15 2019-04-02 伊莱利利公司 作为napi-iib抑制剂的稠合噻吩衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557112B2 (en) * 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
GB0513702D0 (en) * 2005-07-04 2005-08-10 Sterix Ltd Compound
NZ604831A (en) * 2010-07-02 2014-12-24 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
WO2012117097A1 (en) * 2011-03-03 2012-09-07 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
US11000491B2 (en) * 2017-05-05 2021-05-11 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
CA3087830A1 (en) * 2018-02-08 2019-08-15 Enyo Pharma Non-fused thiophene derivatives and their uses
US20210000906A1 (en) * 2018-03-21 2021-01-07 Ionis Pharmaceuticals, Inc. Modulation of hsd17b13 expression

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233246A (zh) * 1996-10-15 1999-10-27 默克专利股份公司 氨基噻吩羧基酰胺及其作为磷酸二酯酶抑制剂的用途
US20060217426A1 (en) * 2003-03-27 2006-09-28 Kirin Beer Kabushiki Kaisha Compound inhibiting in vivo phosphorous transport and medicine containing the same
CN101287728A (zh) * 2005-08-17 2008-10-15 先灵公司 新的高亲和力噻吩基和呋喃基激酶配体
US20150119426A1 (en) * 2012-05-04 2015-04-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Modulators of the relaxin receptor 1
CN105524053A (zh) * 2014-10-19 2016-04-27 广东东阳光药业有限公司 四氢苯并噻吩化合物
US20170096435A1 (en) * 2015-09-30 2017-04-06 Quartet Medicine, Inc. Sepiapterin reductase inhibitors
KR20170092126A (ko) * 2016-02-02 2017-08-10 부산대학교 산학협력단 Ppar, fxr 및 ampk 활성화 효능을 갖는 신규 티오펜 화합물 또는 이의 약제학적으로 허용 가능한 염 및 이의 의학적 용도
CN109563070A (zh) * 2016-08-15 2019-04-02 伊莱利利公司 作为napi-iib抑制剂的稠合噻吩衍生物

Also Published As

Publication number Publication date
EP4185381A4 (en) 2024-08-21
JP2023537271A (ja) 2023-08-31
TW202220967A (zh) 2022-06-01
US20230278978A1 (en) 2023-09-07
EP4185381A1 (en) 2023-05-31
WO2022020714A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
CN116323578A (zh) 噻吩hsd17b13抑制剂及其用途
CN116670118B (zh) 二氯苯酚hsd17b13抑制剂及其用途
CN116194440A (zh) 喹唑啉酮hsd17b13抑制剂及其用途
WO2021211974A1 (en) Hsd17b13 inhibitors and uses thereof
CA2656002A1 (en) Purinone derivatives as hm74a agonists
CN119032090A (zh) 2-取代的噻唑hsd17b13抑制剂及其用途
WO2022216627A1 (en) Thiazole/isothiazole hsd17b13 inhibitors and uses thereof
EP4320111A1 (en) Hydroxypyridine hsd17b13 inhibitors and uses thereof
CN107759588A (zh) 一类苯基‑(吡唑并[1,5‑a]吡啶‑3‑基)甲酮衍生物
US12617772B2 (en) Hydroxypyridine HSD17B13 inhibitors and uses thereof
HK40094120A (zh) 喹唑啉酮hsd17b13抑制剂及其用途
HK40097014A (zh) 二氯苯酚hsd17b13抑制剂及其用途
WO2026064458A1 (en) Hsd17b13 inhibitors and uses thereof
TW202413358A (zh) 用於抑制pkmyt1之化合物及方法
EA049239B1 (ru) Дихлорфенольные ингибиторы hsd17b13 и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095049

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230623